vatalanib has been researched along with pemetrexed in 2 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (pemetrexed) | Trials (pemetrexed) | Recent Studies (post-2010) (pemetrexed) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 2,469 | 657 | 1,695 |
| Protein | Taxonomy | vatalanib (IC50) | pemetrexed (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.1 | |
| Dihydrofolate reductase | Homo sapiens (human) | 4.0309 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 2.3 | |
| Thymidylate synthase | Homo sapiens (human) | 8.1787 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 2.3 | |
| Folate receptor beta | Homo sapiens (human) | 0.2585 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2417 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.0342 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.07 | |
| Reduced folate transporter | Homo sapiens (human) | 0.0928 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 1.655 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.0229 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, W; Freeman, B; Manno, P; Sharma, S; Symanowski, J; Turner, J; Vogelzang, N | 1 |
| Adjei, AA; Lim, VS; Molina, J; Satele, D; Wang, F; Yin, J | 1 |
2 trial(s) available for vatalanib and pemetrexed
| Article | Year |
|---|---|
A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Pemetrexed; Phthalazines; Pyridines | 2009 |
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Phthalazines; Protein Kinase Inhibitors; Pyridines; Random Allocation; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |